novo nordisk mash wegovy

Order byBest matchMost fresh

Novo Nordisk, Liver

Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.

· 1d · on MSN

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

· 4d · on MSN

Novo Nordisk's Wegovy gets accelerated US approval for liver disease MASH

· 1d

Stocks to Watch Monday: Novo Nordisk, TeraWulf, UnitedHealth, Soho House

Shares closed up 3.8% on Monday.

· 1d

Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

· 1d

Novo Advances After US Clears Wegovy for Liver Disease

Medscape1d

Wegovy Approved for MASH With Fibrosis, No Cirrhosis

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis but without cirrhosis.

BioSpace1d

Novo Wins MASH Approval for Wegovy

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according to analysts at BMO Capital Markets.

pharmaphorum1d

Novo Nordisk claims first GLP-1 approval in MASH

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be celebrating a first-in-class approval from the FDA for Wegovy in metabolic dysfunction-associated steatohepatitis (MASH).